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The Institute for Immunology and Informatics (iCubed) at the University of Rhode Island 
held its 8
th
 Annual Vaccine Renaissance on October 13-16, 2014. The conference serves 
as an annual nexus for conversations related to vaccine design, discovery, and vaccine 
acceptance. The annual event strives to provide a unique, interactive forum for the 
discussion of cutting-edge vaccine research, including the design and use of new tools 
and techniques for accelerating vaccine discovery. The conference also provides 
academic researchers, vaccine industry leaders and students of vaccinology with an 
opportunity to foster new professional relationships. Furthermore, the organizers of the 
8
th
 Annual Vaccine Renaissance are committed to extending attendance and presentation 
opportunities to young scientists and „scientific minorities,‟ such as women, students 
from historically black colleges and universities (HBCUs), and individuals not native to 
the United States. The conference organizing committee invites such participants to 
present their research as a poster, and has organized “meet-the-expert” roundtable 
discussions as a way of conferring with experts. 
Participants contributed to reports about developing vaccines against emerging infectious 
diseases and research updates on the effect of the human microbiome in responses to 
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vaccines. Field experts also described new cancer vaccine designs, provided overviews 
on the current state of animal vaccine research, and reported on HPV vaccine acceptance 
by at-risk populations. The four-day symposium included a one-day pre-conference, in 
which participants discussed their research involving the JanusMatrix tool developed by 
De Groot and colleagues [1]. The last day of the event provided opportunities for 
attendees gain hands-on experience in a variety of laboratory techniques as well as 
training on the iVAX suite of bioinformatics tools.   
Nearly 100 individuals from industry, academia, and federal agencies such as the Walter 
Reed Army Institute of Research (WRAIR), the United States Army Medical Research 
Institute of Infectious Diseases (USAMRIID), the Department of Agriculture (USDA), 
and the National Institutes of Health (NIH) attended the conference. In addition to 
luminaries such as Bruno Guy (Sanofi Pasteur), Polly Matzinger (Laboratory of 
Immunogenetics, National Institute of Allergy and Infectious Disease), Thomas Nutman 
(Laboratory of Parasitic Diseases, NIH), Amy Rosenberg (Food and Drug 
Administration), Edward T. Ryan (Massachusetts General Hospital, Harvard Chan 
School of Public Health). Papers were presented by John Julias (United States 
Department of Homeland Security), Kimberly A. Kraynyak (Inovio Pharmaceuticals), 
Steve Meshnick (Department of Epidemiology, UNC Gillings School of Global Public 
Health) and Peter B. McGarvey (Innovation Center for Biomedical Informatics, 
Georgetown University Medical Center). Presenters represented a variety of affiliations 
as well as health-related interests, which stimulated participants to draw inferences and 
conceive connections between their colleagues‟ novel ideas and their individual research 
programs.  
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After the conference, presenters are invited to submit a manuscript related to their 
presentation, to the peer-review journal Human Vaccines & Immunotherapeutics 
(HV&I). Five speakers have accepted the invitation to submit, and their articles can be 
found within the current issue of HV&I. In this 8
th
 compendium of papers, we are pleased 
to offer a selection of reports that focus on the means to rapidly develop safer, more 
effective vaccines. In sequential order of authors and their topics is as follows: Moise et 
al. [2] describes the iVAX suite of tools along with their applications for the design of 
vaccines for Tularemia, Smallpox, H. Pylori, Burkholderia, HCV, Lassa virus or H1N1 
and H7N9. Eickhoff et al. describe the immunoinformatic strategy and in vivo validation 
of the identification of 30 epitopes that could be used in the design of Chagas disease 
vaccine [3]. Rose et al. discuss the choice of the adjuvant during vaccine design and 
demonstrate that while the adjuvants do increase the innate response in mice injected 
with piggyBac plasmids, no adjuvant increases the level of transfection of the antigen [4]. 
Carjaval-Yepes et al. developed a cellular model of IFNAR1-knocked-down avian cells 
that can produce H1N1 viruses and HA protein, and propose an alternative method of 
production of Influenza vaccines [5]. Lastly, Jamieson discusses the genetic and 
environmental factors that influence response to vaccination, with a special emphasis on 
the microbiome [6].   
Two additional papers not included in this compendium have been accepted for 
publication and will be published out soon after the printing of this compendium. In those 
two manuscripts, Hoffmann et al. present their pre-clinical work on the development of a 
cancer vaccine targeting survivin expressing tumor cells. HIvax peptides expressed in 
Fowlpox vectors activate antigen-specific CD4+ and CD8+ T cells in healthy donors, 
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providing a rationale to move on to the clinical stage of the vaccine development [7]. Liu 
et al. present an immunoinformatics analysis of H7N9 T cell epitopes, providing a 
possible explanation for immune resistance to inactivated H7 HA vaccines. The results 
demonstrate that HA epitopes containing TCR facing residues identical to self-proteins 
can activate FoxP3+ Tregs, thus inducing immune tolerance and H7N9 “camouflage” 
from the immune response [8].    
The variety of topics and expertise contained within the following reports is an accurate 
representation of the Vaccine Renaissance and its attendees. Qualitative exit surveys 
suggest that participants appreciate the interactive and interdisciplinary nature of the 
Vaccine Renaissance. The 9
th
 Annual Vaccine Renaissance is scheduled to be held 
November 4-6, 215 in Providence, Rhode Island, with informatics training  held on 
Friday, November 6
th
. Please visit www.immunome.org for a list of speakers and to view 
the schedule of events. 
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